丁酸钠通过表观遗传重编程诱导角膜肌成纤维细胞去分化并抑制纤维化
该研究在人尸体角膜来源的角膜基质成纤维细胞经TGFβ1转化为角膜肌成纤维细胞后,给予丁酸钠(NaB)处理72小时,并在兔碱烧伤角膜纤维化模型中局部应用NaB。结果显示NaB可降低促纤维化标志物表达、增加成纤维细胞标志物FSP1,并减少胶原凝胶收缩和兔角膜混浊。
要点
- NaB处理人角膜肌成纤维细胞后显著降低αSMA、Col-III、FN基因表达并增加FSP1表达。
- NaB降低总HDAC活性,伴αSMA和Col-III启动子高甲基化及FSP1启动子低甲基化。
- 局部NaB可减轻碱烧伤兔角膜混浊,提示表观遗传重编程治疗角膜纤维化潜力。
核心结论
- 通过丁酸钠进行表观遗传重编程诱导角膜肌成纤维细胞去分化,是治疗角膜纤维化的有吸引力策略。
- 研究支持NaB在体外改变肌成纤维细胞表型并在体内减少角膜混浊,但需进一步研究。
研究设计与样本
- 体外使用健康人尸体角膜来源的角膜基质成纤维细胞,经TGFβ1(5ng/ml)转化为角膜肌成纤维细胞,并给予NaB(5 mM)处理72小时。
- 体内使用碱烧伤兔角膜纤维化模型,局部应用NaB,通过立体显微镜和Pentacam成像评估。
主要发现
- NaB处理使角膜肌成纤维细胞形态由肌成纤维细胞样变为成纤维细胞样。
- NaB显著降低αSMA(P = 0.0005)、Col-III(P = 0.011)、FN(P = 0.0004)基因表达,并增加FSP1(P = 0.0004)基因表达。
- NaB显著降低总HDAC活性(P = 0.0009),伴αSMA和Col-III启动子高甲基化及FSP1启动子低甲基化。
- NaB处理后的角膜肌成纤维细胞在胶原凝胶收缩实验中收缩力显著降低(P < 0.0001)。
- 局部NaB治疗明显减轻碱烧伤兔角膜的混浊。
临床怎么用
- NaB可能作为通过表观遗传重编程减少角膜肌成纤维细胞纤维化表型的候选局部治疗药物。
- 临床转化前需进一步开展研究验证NaB在角膜纤维化治疗中的安全性和有效性。
局限性
- 原文结论指出需要额外研究,未报告本研究的其他具体局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Abnormal corneal myofibroblast (CMF) differentiation and persistence in stroma after ocular trauma causes corneal fibrosis and impaired vision. This study tested whether epigenetic reprogramming via sodium butyrate (NaB), histone deacetylase inhibitor, could provoke CMF dedifferentiation into precursor/non-opaque corneal fibroblast/keratocyte (CSF) like cells using human in vitro and rabbit in vivo corneal fibrosis models. METHODS: Healthy human cadaver corneas generated CSFs were converted into CMFs by TGFβ1 (5ng/ml) and grown in -/+ NaB (5 mM) for 72 hours. Quantitative RT-PCR and immunofluorescence measured changes in profibrotic markers (alpha smooth muscle actin [αSMA], collagen-III [Col-III], fibronectin [FN]) and fibroblast marker (fibroblast-specific protein-1 [FSP1]). Epigenetic reprogramming was measured by quantification of total HDAC activity by commercial-kit and DNA methylation using methylation-specific PCR primers for αSMA, Col-III, and FSP1 genes. Collagen gel contraction assay (CGA) evaluated response of NaB on CMF's contractile function. In vivo clinical utility of NaB in reducing corneal fibrosis was evaluated via stereomicroscopy and Pentacam imaging in live rabbits. RESULTS: NaB treatment to CMFs changed myofibroblast-morphology to fibroblast-like and significantly reduced αSMA (P = 0.0005), Col-III (P = 0.011), FN (P = 0.0004), and increased FSP1 (P = 0.0004) gene expression in human in vitro. Additionally, it significantly reduced total HDAC activity (P = 0.0009) with hypermethylation of αSMA, Col-III, and hypomethylation of FSP1 gene promoters. Also, NaB-treated CMFs showed significantly reduced contractility (P < 0.0001) in CGA. Topical NaB treatment markedly reduced opacity in alkali-injured rabbit corneas in vivo. CONCLUSIONS: Dedifferentiation of CMFs via epigenetic reprogramming by NaB offers an attractive approach to treat corneal fibrosis in vivo. Additional studies are warranted.
引用
- Sood S, Sinha NR, Tiwari A, et al. Epigenetic Reprogramming Via Sodium Butyrate Induces Corneal Myofibroblast Dedifferentiation In Vitro and Inhibits Fibrosis In Vivo. Invest Ophthalmol Vis Sci. 2025. PMID: 41283751. doi:10.1167/iovs.66.14.59
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。